These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 31400939)

  • 1. Phosphoramidate derivates as controlled-release prodrugs of l-Dopa.
    Olatunji FP; Kesic BN; Choy CJ; Berkman CE
    Bioorg Med Chem Lett; 2019 Sep; 29(18):2571-2574. PubMed ID: 31400939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-Generation Tunable pH-Sensitive Phosphoramidate-Based Linkers for Controlled Release.
    Choy CJ; Ley CR; Davis AL; Backer BS; Geruntho JJ; Clowers BH; Berkman CE
    Bioconjug Chem; 2016 Sep; 27(9):2206-13. PubMed ID: 27562353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease.
    Zhou T; Hider RC; Jenner P; Campbell B; Hobbs CJ; Rose S; Jairaj M; Tayarani-Binazir KA; Syme A
    Eur J Med Chem; 2010 Sep; 45(9):4035-42. PubMed ID: 20646792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations.
    Di Stefano A; Carafa M; Sozio P; Pinnen F; Braghiroli D; Orlando G; Cannazza G; Ricciutelli M; Marianecci C; Santucci E
    J Control Release; 2004 Sep; 99(2):293-300. PubMed ID: 15380638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of aryl phosphoramidate prodrugs of fosfoxacin and its derivatives.
    Munier M; Tritsch D; Lièvremont D; Rohmer M; Grosdemange-Billiard C
    Bioorg Chem; 2019 Aug; 89():103012. PubMed ID: 31174039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential transbuccal delivery of l-DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue.
    Scaturro AL; De Caro V; Campisi G; Giannola LI
    Drug Deliv; 2016 Sep; 23(7):2355-2362. PubMed ID: 25533875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, metabolism and safety of deuterated L-DOPA (SD-1077)/carbidopa compared to L-DOPA/carbidopa following single oral dose administration in healthy subjects.
    Schneider F; Erisson L; Beygi H; Bradbury M; Cohen-Barak O; Grachev ID; Guzy S; Loupe PS; Levi M; McDonald M; Savola JM; Papapetropoulos S; Tracewell WG; Velinova M; Spiegelstein O
    Br J Clin Pharmacol; 2018 Oct; 84(10):2422-2432. PubMed ID: 29959802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
    Hoon M; Petzer JP; Viljoen F; Petzer A
    Molecules; 2017 Nov; 22(12):. PubMed ID: 29186917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biodegradable microspheres loaded with an anti-Parkinson prodrug: an in vivo pharmacokinetic study.
    D'Aurizio E; Sozio P; Cerasa LS; Vacca M; Brunetti L; Orlando G; Chiavaroli A; Kok RJ; Hennink WE; Di Stefano A
    Mol Pharm; 2011 Dec; 8(6):2408-15. PubMed ID: 22014118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing prodrugs for the treatment of Parkinson's disease.
    Sozio P; Cerasa LS; Abbadessa A; Di Stefano A
    Expert Opin Drug Discov; 2012 May; 7(5):385-406. PubMed ID: 22494466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation mechanisms of nucleoside phosphoramidate prodrugs.
    Freel Meyers CL; Borch RF
    J Med Chem; 2000 Nov; 43(22):4319-27. PubMed ID: 11063626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological activity of novel 5-fluoro-2'-deoxyuridine phosphoramidate prodrugs.
    Freel Meyers CL; Hong L; Joswig C; Borch RF
    J Med Chem; 2000 Nov; 43(22):4313-8. PubMed ID: 11063625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-Dopa prodrugs: an overview of trends for improving Parkinson's disease treatment.
    Di Stefano A; Sozio P; Cerasa LS; Iannitelli A
    Curr Pharm Des; 2011; 17(32):3482-93. PubMed ID: 22074421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation.
    Di Stefano A; Sozio P; Iannitelli A; Marianecci C; Santucci E; Carafa M
    J Drug Target; 2006 Nov; 14(9):652-61. PubMed ID: 17090401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and anti-herpetic activity of phosphoramidate ProTides.
    Maiti M; Persoons L; Andrei G; Snoeck R; Balzarini J; Herdewijn P
    ChemMedChem; 2013 Jun; 8(6):985-93. PubMed ID: 23606629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs.
    Kao HD; Traboulsi A; Itoh S; Dittert L; Hussain A
    Pharm Res; 2000 Aug; 17(8):978-84. PubMed ID: 11028945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aryloxy Triester Phosphoramidates as Phosphoserine Prodrugs: A Proof of Concept Study.
    Miccoli A; Dhiani BA; Thornton PJ; Lambourne OA; James E; Kadri H; Mehellou Y
    ChemMedChem; 2020 Apr; 15(8):671-674. PubMed ID: 32162793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aryloxy phosphoramidate triesters as pro-tides.
    Cahard D; McGuigan C; Balzarini J
    Mini Rev Med Chem; 2004 May; 4(4):371-81. PubMed ID: 15134540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiparkinson prodrugs.
    Di Stefano A; Sozio P; Cerasa LS
    Molecules; 2008 Jan; 13(1):46-68. PubMed ID: 18259129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid differentiation of nucleotide phosphoramidate diastereomers by electrospray ionization tandem mass spectrometry.
    Bao D; Reddy PG; Ross BS; Sofia MJ
    Rapid Commun Mass Spectrom; 2012 Aug; 26(16):1887-92. PubMed ID: 22777791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.